
Nearly $10 million in Valparaiso roads and projects planned for summer of improvements
'With more than 175 miles of roadways, plus sidewalks and pathways, along with water and sewer improvements, we're working smart to enhance and promote sustainability,' Costas said in a release.
'Prior to 2024, the city had been committed to about $3.5 million annually to road maintenance, which was a productive increase over the annual paving budget of just $300,000 when I first took office more than 20 years ago. Certainly, costs have increased, but this aggressive annual budget reflects a renewed priority on roadways.'
The city has launched an aggressive schedule of infrastructure projects this season, working strategically to maximize the miles and lifespan for roadways and capital projects citywide, Costas said.
The 2025 paving program has plans to improve 62 lane miles, plus 40 miles of crack sealing and more than a mile of sidewalks. As part of this year's efforts, the city will also test a new road preservation method called Rejuvenation on 3.5 lane miles of recently resurfaced streets to help extend their lifespan.
Council member Barbara Domer, D-3rd who serves as the council liaison for the Valparaiso Board of Works, began updating the mayor, council and public about progress in the early spring.
'Last month in May the contract was awarded to Milestone for the local streets package for about $2.9 million with an engineering estimate that was $3.2 million, so that was a money savings,' Domer said.
'The 2025 Community Crossings bid went to Rieth Riley Construction for $3.3 million with an engineering estimate of $3.6, also amounting to extra money left over. But for the 2025 sidewalk package, the bid was approved to New Tech for $652,000 and that was a bit over the engineering estimate but overall, between these two packages, we are still under.'
Costas said among the 2025 project highlights this summer is a city and county partnership led by Valparaiso's engineering department to fund needed road improvements to Hayes-Leonard and Bartz roads, stretches shared between city and county jurisdiction. Costas said both roads were candidates for paving based on their low PASER ratings.
As part of the Valparaiso 'thoroughfare plan,' created more than a decade ago, this summer will be the final phase to complete the extension of Goodrich Road between Ransom and Vale Park roads including a pathway on the west side while allowing for improvements to the water main and adding better drainage, according to Costas.
Funding sources for this season's paving program include a $1.5 million Community Crossings matching grant awarded through the Indiana Department of Transportation, as well as funds from the local road and street fund and the motor vehicle fund, along with a short-term bond that will not result in the need to raise any taxes or fees, officials said.
Costas reminded targeted roads are selected for paving based on the national PASER (Pavement Assessment Surface Evaluation Rating) rating system which assigns a value of 1 through 10 to each roadway. The number reflects the quality, including the amount and frequency of cracks and potholes. A brand new road is rated a 10 in contrast to older fractured streets requiring extensive reconstruction ranked at 1 and 2.
The city's engineering department 'combines PASER data with other factors such as functional classification and traffic levels to provide a recommendation. We are also aware of future projects pending with Valparaiso City Services and NIPSCO that might affect the timing of projects,' said Max Rehlander, Valparaiso's director of engineering.
'We work to maximize our funding for the best long-term results.'
In addition to roadway improvements, Valparaiso City Services is focused on $76 million of generational capital improvements in addition to yearly capital replacements to both upgrade and extend the lifespan of the city's water and sewer infrastructure.
'Investment in our utilities' infrastructure ensures clean drinking water, a cleaner environment and important safety features – all necessary in maintaining Valparaiso's quality of life,' VCS Executive Director Steve Poulos said.
Rate adjustments approved in 2024 are funding these projects under a timeline that will continue through 2028.
Among this year's VCS projects is more than $1.4 million in water main replacements as well as critical hydrant and valve replacements, plus sanitary sewer relining and manhole rehabilitation.
In addition, VCS is finalizing plans for the future of Valparaiso's water resources which include further investigation and likely implementation for the introduction of lake water as an additional source.
An interactive project list with a complete listing of roadway and capital projects is available in an interactive map at tinyurl.com/ValpoWorks2025. To report a roadway or sidewalk that needs attention, visit valpo.us and enter key information at the 'Voice a Concern' icon found on the homepage.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
Sarepta Sells Arrowhead Stake to Fund Milestone Payment
Sarepta Therapeutics SRPT announced that it has sold at least $174 million worth of its equity investment in Arrowhead Pharmaceuticals ARWR to help fund a milestone payment to the latter. Shares of Sarepta rose around 9% on Wednesday in response to the announcement. Year to date, the stock has plunged 83.2% compared with the industry's 2% decline. Image Source: Zacks Investment Research SRPT's Deal with Arrowhead Sarepta closed an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals in February 2025. As part of this deal, the company acquired exclusive rights to Arrowhead's four investigational RNA interference (RNAi) therapeutics, each being evaluated in separate phase I/II studies. These are SRP-1001 in facioscapulohumeral muscular dystrophy (FSHD), SRP-1002 in idiopathic pulmonary fibrosis (IPF), SRP-1003 in myotonic dystrophy type 1 (DM1) and SRP-1004 in spinocerebellar ataxia 2 (SCA2). The decision to sell its equity investment in Arrowhead was triggered by Sarepta's $100 million milestone payment obligation to the former related to the phase I/II study of SRP-1003 for treating DM1. The phase I/II study met the first of the two predetermined enrollment targets, and a safety review allowed the study to move to higher doses. This milestone triggered a $100 million payment from Sarepta to Arrowhead. Initial data from the study is expected to be released in the second half of 2025. Early data from the FSHD program is also expected later this year. Sarepta has already sold 9.26 million shares of common stock of Arrowhead in a private sale, from which it expects to receive at least $174 million in cash proceeds. Separately, Arrowhead will also buy back $50 million of its own stock from Sarepta to prefund half of the $100 million milestone payment that Sarepta owns. SRPT Stock on Investors' Radar Sarepta has been facing a lot of heat from investors after three patient deaths were linked to its gene therapy treatments and attributed to acute liver failure. While two deaths occurred in patients after receiving Elevidys, one was caused by an experimental limb-girdle muscular dystrophy (LGMD) therapy. All deaths occurred in non-ambulatory patients and were linked to the AAVrh74 gene therapy vector, used in both Elevidys and Sarepta's experimental LGMD therapies. While the two Elevidys deaths had initially prompted Sarepta to suspend Elevidys dosing for non-ambulatory patients, the death of an ambulatory DMD patient in Brazil post-treatment with the therapy led to the product being withdrawn completely from the market. However, the FDA cleared Elevidys for use in ambulatory patients last week after finding no link between the therapy and the Brazilian patient's death. Last week, Sarepta announced that it had resumed delivery of Elevidys shipments. To address the safety issue in non-ambulatory patients, Sarepta is working to create a new protocol with an enhanced immunosuppression regimen to make Elevidys administration safer for non-ambulatory DMD patients. The company also plans to submit these findings to the FDA in hopes of resuming dosing in the non-ambulatory patient population. The company relies heavily on Elevidys to drive top-line growth, with the therapy contributing over half of total revenues. The emerging safety concerns with the drug may hurt sales in future quarters. Last month, Sarepta initiated a restructuring plan to save nearly $400 million annually starting in 2026. To achieve this target, the company has decided to lay off 36% of its workforce — around 500 employees — which is expected to save nearly $120 million per year. As part of this shift, Sarepta is now focusing on its siRNA pipeline acquired from Arrowhead Pharmaceuticals. Sarepta developed Elevidys in partnership with pharma giant Roche RHHBY. In 2019, the company and Roche entered into a licensing agreement to develop Elevidys. Per the agreement, Roche has exclusive rights to launch and market the therapy in non-U.S. markets. SRPT Zacks Rank Sarepta has a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Sarepta Therapeutics, Inc. Price and Consensus Sarepta Therapeutics, Inc. price-consensus-chart | Sarepta Therapeutics, Inc. Quote Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Bloomberg
4 days ago
- Bloomberg
Trump, Witkoff Sons Test Limits of Crypto Hoarding With New Deal
Eric Trump and Donald Trump Jr. grinned as confetti rained down at Nasdaq Inc. in Times Square on Wednesday. The president's sons arrived to celebrate the newest deal for the crypto company they co-founded, World Liberty Financial. Nasdaq Chief Executive Officer Adena Friedman called the moment a 'significant milestone' that puts a public company, pairing up with the roughly one-year-old World Liberty, at the 'forefront of decentralized finance.'
Yahoo
6 days ago
- Yahoo
US national debt hits record $37 trillion
The U.S. national debt surpassed $37 trillion for the first time in the nation's history on Friday as the federal government continues to accumulate debt at a record-setting pace. New data from the Treasury Department released showed that the gross national debt hit $37,004,817,625,842.56 on Tuesday afternoon. Shop Top Mortgage Rates A quicker path to financial freedom Personalized rates in minutes Your Path to Homeownership Treasury's Bessent Says Us Is 'Never Going To Default' As Debt Limit Deadline Looms The $37 trillion debt milestone comes less than eight months after the nation hit the $36 trillion threshold for the first time in late November 2024, and a little over one year after the $35 trillion mark was reached in late July 2024. The U.S. topping $37 trillion in total debt comes as the total debt held by the public – a metric favored by economists that excludes debt held in intragovernmental accounts like the Social Security trust funds – is projected to reach 99% of the size of the U.S. gross domestic product (GDP) this year. Maya MacGuineas, president of the Committee for a Responsible Federal Budget (CRFB) reacted, telling Fox Business, "Reaching this milestone is a moment no one in Washington can be proud of – our fiscal situation is woefully unbalanced, yet Congress keeps on making the situation worse. Even when measuring debt as a share of the economy, we're headed toward record levels and on course to spend $1 trillion just on interest costs. We will need to act quickly to face the reality of our unsustainable debt, before a fiscal emergency forces our hand." Read On The Fox Business App Moody's Downgrades Us Credit Rating Over Rising Debt Michael A. Peterson, CEO of the Peter G. Robinson Foundation, told Fox Business, "The national debt soaring past $37 trillion sends yet another clear message about America's unsustainable fiscal path. Our national debt is now greater than the economies of the entire Eurozone and China, combined." Peterson continued, "Despite today's unfortunate milestone, it's not too late to act. We should reform our budget before the damage is made even worse. Policymakers have many well-known options to stabilize our debt and put us on a stronger path for the next generation." This is a developing story. Please check back for article source: US national debt hits record $37 trillion Sign in to access your portfolio